Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3 development in second half of 2017 WALTHAM, Mass., May 15, 2017 ( …